Wissenschaft und Lehre

Ulrich Dührsen Gabriele Prange‑Krex Regina Moeller Harald Held Gerhard Heil Andreas Schwarzer Stefan Mahlmann Ariane Dienst Matthias Sandmann Georg Maschmeyer Jochen Schütte Dennis Hahn Michael Heike Michael Nonnemacher Christine Hanoun Andreas Hüttmann
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial
Annals of Hematology 21.05.2025 Publication Link | DOI Link

Ruth Elisa Eyl-Armbruster, Julia Wendler; Ramona Böttinger, Simone Neumaier, Antje Jensch Susanne Walz Markus Knott; Susanne Rössle Nicola Giesen Jessika Strentzsch Veronika Schindler Hans-Georg Kopp Jochen Greiner; Claudio Denzlinger; Gerald Illerhaus
Study of long-term survivorship of lymphoma patients-a multicenter longitudinal study of return to work and quality of life
Oncology Research and Treatment 15.02.2024

Anna Brandt,Konrad Klinghammer,Christoph Schultheiss,Lisa Paschold,Claudia Wickenhauser, Marcus Bauer,Anna Bergqvist, Dennis Hahn, Philippe Schafhausen, Mareike Tometten, Markus Blaurock, Henrike Barbara Zech,Chia-Jung Busch, Andreas Dietz, Urs Muller-Richter, Jurgen Alt, Andreas Boehm, Simone Kowoll,Jörg Steighardt,Alexander Lasch, Ingunn Hagen Westgaard,Marita Westhrin, Alexander Stein,Axel Hinke, and Mascha Binder
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial
Med Journal 11.7.2025 Publication Link | DOI Link

Latzer, P. Zelba, H. Battke, F. Reinhardt, A. Shao, B. Bartsch, O. Rabsteyn, A. Harter, J. Schulze, M. Okech, T. Golf, A. Kyzirakos-Feger, C. Kayser, S. Pieper, N. Feldhahn, M. Wünsche, J. Seitz, C. Hadaschik, D. Garbe, C. Illerhaus, G. Biskup, S.
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Nature Communications 11.08.2024

Jensch, A., Mennig, E., Walz, S., Neumaier, S., Eyl-Armbruster, R. E., Knott, M., ... & Illerhaus, G.
Association of functional status, blood biomarkers and overall survival in older patients with lymphoma-a monocentric, retrospective study
Oncology Research and Treatment, 15.02.2024 DOI Link

Schorb, E. Isbell, L. K. Kerkhoff, A. Mathas, S. Braulke, F. Egerer, G. Röth, A. Schliffke, S. Borchmann, P. Brunnberg, U. Kroschinsky, F. Möhle, R. Rank, A. Wellnitz, D. Kasenda, B. Pospiech, L. Wendler, J. Scherer, F. Deckert, M. Henkes, E. von Gottberg, P. Gmehlin, D. Backenstraß, M. Jensch, A. Burger-Martin, E. Grishina, O. Fricker, H. Malenica, N. Orbán, A. Duyster, J. Ihorst, G. Finke, J. Illerhaus, G.
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
Lancet. Haematology 11.03.2024

Lauer, E. M. Riegler, E. Mutter, J. A. Alig, S. K. Bleul, S. Kuehn, J. Ranganathan, L. Klingler, C. Demerath, T. Würtemberger, U. Rau, A. Weiß, J. Eisenblaetter, M. Bamberg, F. Prinz, M. Finke, J. Duyster, J. Illerhaus, G. Diehn, M. Scherer, F.
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas
Neuro-Oncology 02.02.2024

Ferreri, A. J. M. Illerhaus, G. Doorduijn, J. K. Auer, D. P. Bromberg, J. E. C. Calimeri, T. Cwynarski, K. Fox, C. P. Hoang-Xuan, K. Malaise, D. Ponzoni, M. Schorb, E. Soussain, C. Specht, L. Zucca, E. Buske, C. Jerkeman, M. Dreyling, M. EHA, & Committees
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
HemaSphere 04.06.2024

Diaz Ochoa, J. G., Mustafa, F. E., Weil, F., Wang, Y., Kama, K., & Knott, M
The aluminum standard: using generative Artificial Intelligence tools to synthesize and annotate non-structured patient data
BMC Medical Informatics and Decision Making 28.12.2024

Anna Brandt Christoph Schultheiss Konrad Klinghammer Philippe Schafhausen Chia-Jung Busch Markus Blaurock Axel Hinke Mareike Tometten Andreas Dietz Urs Müller-Richter Dennis Hahn Jürgen Alt Alexander Stein Mascha Binder
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial
Frontiers in Oncology 7.02.2024 DOI Link

Heitmann JS Jung S Wacker M Maringer Y Nelde A Bauer J Denk M Hoenisch-Gravel N Richter M Oezbek MT Dubbelaar ML Bilich T Pumptow M Martus P Illerhaus G Denzlinger C Steinbach F Aulitzky WE Müller MR Dörfel D Rammensee HG Salih HR Walz JS.
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.
Front Immunol 26.11.2024

Isbell LK Uibeleisen R Friedl A Burger E Dopatka T Scherer F Orban A Lauer E Malenica N Semenova I Vreden A Valk E Wendler J Neumaier S Fricker H El Rabih AAH Gloggengießer C Hilbig D Bleul S Weis J Gmehlin D Backenstrass M Wirtz S Ihorst G Finke J Illerhaus G Schorb E
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial
BMC Cancer 18.08.2023

Döhner H Weber D Krzykalla J Fiedler W Kühn MWM Schroeder T Mayer K Lübbert M Wattad M Götze K Fransecky L Koller E Wulf G Schleicher J Ringhoffer M Greil R Hertenstein B Krauter J Martens UM Nachbaur D Samra MA Machherndl-Spandl S Basara N Leis C Schrade A Kapp-Schwoerer S Cocciardi S Bullinger L Thol F Heuser M Paschka P Gaidzik VI Saadati M Benner A Schlenk RF Döhner K Ganser A
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
Lancet Haematol Juli 2023

Khwaja J Kirkwood AA Isbell LK Steffanoni S Goradia H Pospiech L Fail T Nicholson E Fletcher K Linton KM Parsons KE Elmusharaf N Eccersley L Eyre TA Chaganti S Smith J Thakrar N Kutilina A Calimeri T Martinez-Calle N El-Sharkawi D Osborne W Illerhaus G Fox CP Ferreri AJM Schorb E Cwynarski K
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma
Haematologica 01.03.2023

Carton M, Del Castillo JP, Colin JB, Kurtinecz M, Feuilly M, Pierron G, Arvis P, Khadir SK, Sparber-Sauer M, Orbach D.
Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.
"Future Oncol. 2023 Aug;19(24):1645-1653. doi: 10.2217/fon-2023-0114. Epub 2023 May 3. PMID: 37133249" 2023

Isbell LK Tschuch C Doostkam S Waldeck S Andrieux G Shoumariyeh K Lenhard D Schaefer HE Reinacher PC Bartsch I Pantic M Vinnakota JM Kakkassery V Schorb E Scherer F Frey AV Boerries M Illerhaus G Duyster J Schueler J von Bubnoff N
Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma
Neuropathol Appl Neurobiol April 2023

Ferreri AJM Calimeri T Cwynarski K Dietrich J Grommes C Hoang-Xuan K Hu LS Illerhaus G Nayak L Ponzoni M Batchelor TT
Primary central nervous system lymphoma
Nat Rev Dis Primers 15.06.2023

Lorenzen S Schwarz A Pauligk C Goekkurt E Stocker G Knorrenschild JR Illerhaus G Dechow T Moehler M Moulin JC Pink D Stahl M Schaaf M Goetze TO Al-Batran SE
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III R
BMC Cancer 19.06.2023

Hammersen J Birndt S Döhner K Reuken P Stallmach A Sauerbrey P La Rosée F Pfirrmann M Fabisch C Weiss M Träger K Bremer H Russo S Illerhaus G Drömann D Schneider S La Rosée P Hochhaus A
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Leukemia 28.07.2023

Treiber H Nilius-Eliliwi V Seifert N Vangala D Wang M Seidel S Mika T Marschner D Zeremski V Wurm-Kuczera R Caillé L Chapuy CI Trümper L Fischer T Altenbuchinger M Wulf GG Illerhaus G Dietrich S Schroers R Chapuy B
Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients
Hemasphere 21.07.2023

Mutter JA Alig SK Esfahani MS Lauer EM Mitschke J Kurtz DM Kühn J Bleul S Olsen M Liu CL Jin MC Macaulay CW Neidert N Volk T Eisenblaetter M Rauer S Heiland DH Finke J Duyster J Wehrle J Prinz M Illerhaus G Reinacher PC Schorb E Diehn M Alizadeh AA Scherer F
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas
 J Clin Oncol 21.12.2022